Scilex Holding Co (SCLXW) stock
SCLXWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as SCLX
$0.04−0.00 (-1.53%)
Close on Oct 30, 2026Market cap $17.50MP/E –Yield –
Scilex operating margin
Operating margin is operating income as a percentage of revenue.
Scilex's operating margin for the twelve months ending Jun 30, 2026 was -1136.4%. For fiscal 2025 it was -1143.7%, against -147.4% the year before. The highest annual figure on record is -114.4% in fiscal 2021.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -1143.7% | −996.3 |
| FY2024 | Dec 31, 2024 | -147.4% | +78.2 |
| FY2023 | Dec 31, 2023 | -225.6% | −92.4 |
| FY2022 | Dec 31, 2022 | -133.1% | −18.7 |
| FY2021 | Dec 31, 2021 | -114.4% | +35.2 |
| FY2020 | Dec 31, 2020 | -149.7% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -385.0% | −177.8 |
| Q1 FY2026 | Mar 31, 2026 | -373.5% | +184.0 |
| Q4 FY2025 | Dec 31, 2025 | -2317.8% | −2127.3 |
| Q3 FY2025 | Sep 30, 2025 | -1766.2% | −1628.2 |
| Q2 FY2025 | Jun 30, 2025 | -207.2% | −111.8 |
| Q1 FY2025 | Mar 31, 2025 | -557.5% | −378.6 |
| Q4 FY2024 | Dec 31, 2024 | -190.5% | −54.2 |
| Q3 FY2024 | Sep 30, 2024 | -138.0% | +245.6 |
| Q2 FY2024 | Jun 30, 2024 | -95.4% | +85.9 |
| Q1 FY2024 | Mar 31, 2024 | -179.0% | +61.8 |
| Q4 FY2023 | Dec 31, 2023 | -136.2% | +29.4 |
| Q3 FY2023 | Sep 30, 2023 | -383.6% | −290.3 |
| Q2 FY2023 | Jun 30, 2023 | -181.3% | −36.6 |
| Q1 FY2023 | Mar 31, 2023 | -240.7% | −111.4 |
| Q4 FY2022 | Dec 31, 2022 | -165.6% | – |
| Q3 FY2022 | Sep 30, 2022 | -93.3% | – |
| Q2 FY2022 | Jun 30, 2022 | -144.7% | – |
| Q1 FY2022 | Mar 31, 2022 | -129.3% | – |